DiaGenic ASA Presents New Data for Differentiating Alzheimer’s Disease Dementia From Other Forms of Dementia With High Accuracy
Published: Nov 08, 2012
OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG): New results from re-evaluation of two separate and previously performed clinical trials show that DiaGenic’s technology has the potential to differentiate dementia due to Alzheimer’s disease (AD) from other forms of dementia. In one study, which included 103 patients with AD and 40 patients with other types of dementia and related disorders, AD was correctly identified and separated from other types of dementia with an accuracy of 89%. In a second study which included 25 patients with AD and 30 patients with other types of dementia, the diagnostic accuracy was 82%.